8-K: Sanara MedTech Reports Strong Q3 Surgical Growth Amid THP Exit

Sanara MedTech Inc. announced its third quarter 2025 financial results, reporting a 22% year-over-year net revenue increase driven by its core surgical business, alongside a significant net loss due to discontinued operations.

Summary

• Net revenue increased 22% year-over-year to $26.3 million in Q3 2025, compared to $21.7 million in Q3 2024.
• Net revenue for the first nine months of 2025 increased 25% to $75.6 million, compared to $60.4 million in the first nine months of 2024.
• Net income from continuing operations was $0.8 million in Q3 2025, a significant improvement from a net loss of $0.2 million in Q3 2024.
• Adjusted EBITDA increased to $4.9 million in Q3 2025, up from $2.6 million in Q3 2024.
• The company initiated a strategic realignment, ceasing operations of Tissue Health Plus (THP) to focus on its core surgical business.
• As a result of the THP discontinuation, a noncash asset impairment charge of $26.5 million was recorded in Q3 2025.
• The total net loss for Q3 2025 was $30.4 million, compared to a net loss of $2.9 million in Q3 2024, primarily due to the THP impairment.
• Seth Yon was appointed President and Chief Executive Officer, effective September 15, 2025, succeeding Ron Nixon who continues as Executive Chairman.

Sentiment

Score: 4

Explanation: While the core surgical business demonstrated strong revenue growth and improved profitability from continuing operations, the overall net loss of $30.4 million due to a significant noncash asset impairment charge from discontinued operations is a major negative. The strategic realignment is a positive long-term move, but the immediate financial impact is substantial, creating mixed sentiment.

Positives

• Net revenue increased 22% year-over-year in Q3 2025 to $26.3 million, demonstrating strong top-line growth.
• Net revenue increased 25% year-over-year in the first nine months of 2025 to $75.6 million.
• Net income from continuing operations improved to $0.8 million in Q3 2025, reversing a $0.2 million net loss in Q3 2024.
• Adjusted EBITDA significantly increased to $4.9 million in Q3 2025 from $2.6 million in Q3 2024, indicating improved operational profitability.
• Gross margin improved to 93% of net revenue in Q3 2025, up from 91% in Q3 2024, driven by increased sales of soft tissue repair products.
• Sales of surgical soft tissue products, including CellerateRX Surgical and BIASURGE, increased by 24%, reflecting successful commercial strategy and market penetration.
• Net cash provided by operating activities in Q3 2025 was $2.2 million, compared to $2.1 million in Q3 2024, showing positive cash generation from operations.
• Net cash provided by operating activities for the first nine months of 2025 was $2.8 million, a significant improvement from $1.0 million of net cash used in operating activities in the first nine months of 2024.

Negatives

• The company reported a substantial net loss of $30.4 million for Q3 2025, significantly higher than the $2.9 million net loss in Q3 2024.
• The increased net loss is primarily due to a $26.5 million noncash asset impairment charge related to the discontinued Tissue Health Plus (THP) operations.
• Net loss from discontinued operations for Q3 2025 was $31.2 million, compared to $2.7 million in Q3 2024.
• Long-term debt increased to $45.1 million as of September 30, 2025, from $30.7 million as of December 31, 2024.
• Cash decreased to $14.9 million as of September 30, 2025, from $15.9 million as of December 31, 2024.
• Other expense increased to $2.1 million in Q3 2025 from $1.0 million in Q3 2024, primarily due to higher interest expense and share of losses from equity method investments.

Risks

• Uncertainties associated with the development and process for obtaining regulatory approval for new products.
• The company's ability to build out its executive team.
• The company's ability to identify and effectively utilize the net proceeds of the CRG Term Loan Agreement to support growth initiatives.
• The extent of product demand, market and customer acceptance.
• The effect of economic conditions.
• Competition in the surgical market.
• Pricing pressures on products.
• The ability to consummate and integrate acquisitions.

Future Outlook

Management expects to continue executing its commercial plan, improve operational efficiency, and invest wisely in its surgical business for the remainder of 2025 and beyond. These efforts are anticipated to support strong, sustainable revenue growth and improved profitability.

Management Comments

• "Our surgical team delivered strong sales performance in the third quarter, culminating in net revenue growth of 22% year-over-year." Seth Yon, President and CEO.
• "Our net revenue growth was fueled by a 24% increase in sales of our surgical soft tissue products, including CellerateRX Surgical and BIASURGE." Seth Yon.
• "This performance reflects the success of our commercial strategy to develop relationships with independent distributors, expand into new healthcare facilities, and penetrate existing facilities by adding new surgeon users." Seth Yon.
• "We achieved notable year-over-year improvements in our profitability profile, with a $1.0 million improvement in net income from continuing operations and a $2.3 million improvement in Adjusted EBITDA, on net revenue growth of $4.7 million year-over-year." Seth Yon.
• "Regarding THP, as outlined in our press release yesterday, we have completed a thorough assessment of strategic alternatives for THP and initiated a realignment of our portfolio in the third quarter. Accordingly, we have ceased THPs operations to enhance operational efficiency and allocate resources to our core surgical business." Seth Yon.
• "We believe this focus will support sustained long-term growth and value creation." Seth Yon.
• "For the remainder of 2025, our team will continue to execute our commercial plan, improve our operational efficiency, and invest wisely in our surgical business. We expect these efforts to support strong, sustainable revenue growth and improved profitability, both this year and beyond." Seth Yon.

Industry Context

Sanara MedTech operates in the competitive surgical market, focusing on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures. The company's strategic realignment to cease Tissue Health Plus (THP) operations and concentrate on its core surgical business (soft tissue repair and bone fusion products) reflects a strategic move towards specialization and efficiency. The reported growth in surgical soft tissue products like CellerateRX Surgical and BIASURGE indicates successful market penetration and effective distribution strategies within the North American surgical tissue repair markets, aligning with broader industry trends towards specialized, high-value medical technologies.

Management Changes

Related Party Transactions

• Accounts receivable related parties: $0 as of September 30, 2025 (compared to $40,566 as of December 31, 2024).
• Accounts payable related parties: $27,339 as of September 30, 2025 (compared to $30,913 as of December 31, 2024).

Stakeholder Impact

• Shareholders: Impacted by the significant net loss due to the THP impairment, but may benefit from the strategic focus on the profitable core surgical business for long-term value creation.
• Employees: The cessation of Tissue Health Plus (THP) operations likely resulted in workforce adjustments within that segment.
• Customers: The company's continued focus on its core surgical business aims to provide better clinical outcomes and reduce healthcare expenditures in the surgical market, potentially benefiting customers through enhanced product offerings and services.

Next Steps

• Continue to execute the commercial plan for the core surgical business.
• Improve operational efficiency across the company.
• Invest wisely in the surgical business to support sustained growth.
• Evaluate and potentially utilize the remaining $12.25 million borrowing capacity before December 31, 2025.

Key Dates

Recommendation

While Sanara MedTech's core surgical business demonstrates strong revenue growth and improved profitability from continuing operations, the substantial net loss of $30.4 million, driven by a significant noncash asset impairment charge from discontinued operations, introduces considerable short-term uncertainty. The strategic realignment to focus on the core business is a positive long-term move, but investors should monitor the successful integration of this new focus and the company's ability to manage its increased debt and potential further borrowing without excessive dilution or burden. The stock is likely to experience volatility due to the large reported loss, but the underlying business performance in continuing operations suggests potential for recovery once the impact of the discontinued operations is fully absorbed.

Keywords

medical technology, surgical market, Q3 2025 earnings, financial results, net revenue growth, Adjusted EBITDA, discontinued operations, asset impairment, soft tissue repair, bone fusion, CellerateRX Surgical, BIASURGE, CEO appointment, corporate strategy